Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: GlobalData
$125.00
Provider: Wright Reports
$75.00
Provider: Edison Investment Research
$10.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Orexo AB Updates on Launch Preparations for Zubsolv in United States; Plans to Establish ADR Program


Thursday, 5 Sep 2013 03:30am EDT 

Orexo AB announced that preparations for launch of Zubsolv (buprenorphine and naloxone) sublingual tablets (CIII) has been progressing according to plans and that Zubsolv will be available in pharmacies across the United States from September 16. Zubsolv will at launch be reimbursed in more than 70% of the current market for opioid replacement therapy. As a result of the positive response in the United States (U.S.) and growing interest in Orexo, a process has been initiated to improve access for U.S. investors to trade in the Company's shares by establishment of a sponsored level 1 American Depositary Receipt (ADR) program. Further details pertaining to this are be provided at a later stage. 

Company Quote

142.0
 --
27 Jan 2015